27.12.2022 - Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA for Patients with Urea Cycle Disorders 27-Dec-2022 / 07:00 CET/CEST Release of an ad hoc announcement .
Relief Therapeutics Holding SA / Key word(s): Regulatory Approval27-Dec-2022 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with.
Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA for Patients with Urea Cycle Disorders 27-Dec-2022
Relief Therapeutics Holding SA / Key word: Regulatory Approval
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders. | December 27, 2022